PRESS RELEASE Paris

Sanofi delivered 2015 business EPS up 8.5% on a reported basis

and stable at constant exchange rates consistent with guidance

Executing on 2020 strategic roadmap

Recent achievements in advancing Sanofi s R&D pipeline of innovative medicines

growth in Pharmaceuticals, Vaccines and Animal Health in 2015

financial results in 2015 while making significant investments in new product launches

2016 financial guidance

Sanofi Chief Executive Officer, Olivier Brandicourt, commented:

In 2015, Sanofi made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization.

Entering into exclusive negotiations on a business swap with Boehringer Ingelheim would bring us leadership in CHC. This is a key first step in reshaping our portfolio. In 2016, we continue to allocate resources to our promising late-stage pipeline

and the introduction of innovative medicines which will position us for accelerated future growth .

Following the announcement of exclusive negotiations with Boehringer Ingelheim and as the IFRS 5 presentation requirement

for discontinued operations, net income for Sanofi s Animal Health business (Merial) will be reported on a separate line ( net income from the held for exchange Animal Health Business ) in the Consolidated Income Statement for 2015

and the prior year. Until the closing of the transaction, Sanofi will continue to manage and report the performance of the Animal Health business, which will remain an operating segment consistent with IFRS 8 and be included in the key performance

indicators of the Group.

Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media

Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com

Web site: www.sanofi.com Mobile app: SANOFI IR

available on the App Store and Google Play

2015 fourth-quarter and full-year Aggregate Group sales

Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER(1).

Fourth-quarter Aggregate Group sales were 9,278 million up 2.3% at 2015 exchange rates. Exchange rate movements had a positive effect of 3.9

percentage points reflecting mainly the strength of the U.S. dollar against the Euro, which largely offset the negative effect of the Brazilian real and the Russian Ruble. At CER, Aggregate Group sales decreased 1.6%. This includes the impact of the

voluntary recall of Auvi-Q /Allerject in the U.S. and Canada announced on October 30. The negative impact of the recall on sales was

- 122 million which corresponded mainly to the reversal of sales of the product since the beginning of 2015. Excluding

AuviQ /Allerject , Aggregate Group sales were down 0.3% at CER.

In 2015, Aggregate Group sales were 37,057 million, up 9.7% at 2015 exchange rates. Exchange rate movements had a favorable effect of 7.5 percentage

points resulting in an increase of aggregate Group sales of 2.2% at CER.

Fourth-quarter sales for Pharmaceuticals decreased 4.7% to 7,277 million impacted by a decline in Diabetes and Established Rx Products that was partially

offset by Genzyme. Excluding AuviQ /Allerject , sales for Pharmaceuticals were down 3.2%. In 2015, sales for Pharmaceuticals increased

0.8% to 29,799 million.

In the fourth quarter, sales of Diabetes decreased 12.6% to 1,903 million, reflecting lower sales of Lantus in the U.S. In 2015, sales of Diabetes were 7,580 million, down 6.8% and in line with the guidance communicated in October.

In the U.S., fourth-quarter sales of Diabetes were down 25.1% to 1,056 million. Sales of Diabetes outside

the U.S. were 847 million, an increase of 7.0% supported by the strong performance in Emerging Markets up 15.1% to 426 million. Sales in Western Europe reached 302 million, up 1.0% reflecting glargine biosimilar competition.

Toujeo , the new-generation basal insulin, was launched in the U.S. market at the end of March

and later in the year in other key global markets. Total sales of the product were 98 million in the fourth quarter compared to 46 million in the third quarter of 2015. In the U.S. sales of Toujeo were 79 million reflecting strong adoption by prescribers supported by rapid and broad commercial and Medicare market access.

Toujeo is now available globally in more than 20 countries and generated full year 2015 sales of 164 million including 27 million outside the U.S.

Fourth-quarter sales of Sanofi s glargine franchise (Lantus and Toujeo ) were 1,634 million, down 14.9%. Over the quarter, sales of Lantus were 1,536 million down 19.9%. In the U.S., as

anticipated, sales of Lantus decreased 31.6% to 933 million mainly reflecting higher discounts as compared to last year, a slowdown of basal insulin market growth and an unfavorable mix

effect towards highly-discounted government channels such as Medicaid (which also included Medicaid delayed bills from multiple States). In Western Europe, sales of Sanofi s glargine franchise were up 0.4% to 231 million reflecting the

launch of a biosimilar glargine in the second half of 2015 in several European markets. In Emerging Markets, fourth-quarter sales of Sanofi s glargine franchise were 304 million, up 17.2%, driven by Lantus in China, Middle East, Russia and Turkey. In 2015 sales of Sanofi s glargine franchise were 6,554 million, down 8.5%.

Fourth-quarter sales of Amaryl were stable at 94 million, of which 76 million

were generated in Emerging Markets (up 4.2%). In 2015, Amaryl sales were up 1.7% to 393 million. Fourth-quarter sales of

Apidra increased 3.1% to 104 million, reflecting lower sales in the U.S. (-12.2% to 42 million). In Emerging Markets, sales of Apidra increased 19.0% to 24 million. In 2015, sales of Apidra were up 4.8% to 376 million.

Afrezza sales were 2 million and 7 million in the fourth quarter and 2015,

respectively. On January 4, 2016, Sanofi informed MannKind Corporation, that it has exercised its option to terminate its agreement. This termination will become effective on April 4, 2016. This action is in line with the terms of the contract, and

the decision to terminate is due to a number of factors, including the continued low level of prescriptions for Afrezza despite Sanofi s substantial efforts. Sanofi intends to work with

MannKind to support a smooth transition and will continue to make Afrezza available in the United States for a period of up to approximately 180 days after the date of Termination, as set

forth in the License and Collaboration Agreement.

Following European approval in September 2015, Praluent (alirocumab, collaboration with

Regeneron) was launched in the UK, Germany and Nordic countries in the fourth quarter. In the U.S., Praluent was launched in July and is now accessible on formularies covering over 170

million lives in the U.S. In addition to the significant market access achieved, Praluent is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies. Worldwide sales of

Praluent were 5 million and 9 million in the fourth quarter and full year of 2015, respectively.

Fourth-quarter sales of Genzyme increased 28.2% to 1,013 million driven by Aubagio and the launch progress of Lemtrada . Genzyme delivered strong performance across all geographies with the U.S. up 42.1% to 485

million and Western Europe up 25.3% to 290 million over the period. In Emerging Markets, sales were 148 million, up 9.7% in the fourth quarter. In 2015, sales of Genzyme increased 29.5% to 3,664 million.

Sales of Multiple Sclerosis products increased 99.4% to 353 million in the fourth quarter. In 2015,

sales of this franchise grew 112.2% exceeding 1 billion in annual sales for the first time ( 1,114 million).

Fourth-quarter sales of

Aubagio were up 69.9% to 272 million driven by the U.S. (up 57.4% to 194 million) and Western Europe ( 58 million in sales). In Western Europe, Aubagio exceeded 15% market share in France and some Nordic countries. In 2015, sales of Aubagio increased 77.8% to 871 million.

Fourth-quarter sales of Lemtrada were 81 million including 44 million in the U.S.

and 28 million in Western Europe, mainly in Germany and the UK. In 2015, sales of Lemtrada were 243 million compared to 34 million in 2014.

Sales of Rare Disease products were up 8.4% to 660 million in the fourth quarter and 11.4% to 2,550 million in 2015.

Sales of the Gaucher franchise reached 202 million in the fourth quarter, down 1.5% and reflecting lower sales in Emerging markets of Cerezyme ( 59 million, down 14.7%) due to lower Russian government purchasing. In the U.S., fourth-quarter sales of the Gaucher franchise increased 11.5% to 66 million reflecting decreased

sales of Cerezyme ( 47 million, down 12.5%) which were more than offset by Cerdelga sales ( 19 million versus 4

million in Q4 2014), the only first-line oral therapy for Gaucher disease type 1 patients. In Western Europe, where Cerdelga is now available in several countries (Germany, France, Denmark,

Norway and Sweden), sales of the Gaucher franchise were 64 million, up 3.2%. In 2015, sales of the Gaucher franchise increased 8.6% to 823 million, mainly reflecting new patient accrual by Cerdelga .

Fourth-quarter sales of Fabrazyme

increased 20.3% to 158 million. The product recorded strong performance in the U.S. (up 20.3% to 82 million), Western Europe (up 17.2% to 35 million), and Emerging Markets (up 46.7% to 19 million) reflecting new patient

accrual. In 2015, sales of Fabrazyme increased 17.2% to 592 million.

Myozyme /Lumizyme were 167 million, an increase of 6.7% in the fourth quarter, driven by the U.S. (up 9.3% to

55 million) and Emerging markets (up 11.5% to 28 million). In Western Europe, sales were stable at 72 million. In 2015, sales of Myozyme /Lumizyme were 650 million, an increase of 12.4%.

Sales of Consumer Healthcare (CHC) products were 809 million in the fourth quarter, an increase of 1.0% driven by

higher sales in Australia and Mexico. Over the quarter, sales of CHC in the U.S. were up 0.6% to 197 million reflecting lower sales of Nasacort compared to strong sales following the

product launch in 2014. Fourth-quarter sales of CHC in Emerging Markets were stable at 392 million, with lower sales in Venezuela offsetting the recovery in Mexico. In Western Europe, sales were flat at 159 million in the quarter,

impacted by a second price decrease of Doliprane in France in November. In the Rest of the World, fourth-quarter sales grew 12.5% to 61 million driven by Australia. In 2015, sales of

CHC reached 3,492 million, an increase of 2.8%.

Fourth-quarter sales of Generics increased 4.7% to 467 million driven by sales in Western Europe (up 9.8% to 150 million) and sales of

authorized generics version of Lovenox in the U.S. and Plavix in Japan. In Emerging Markets, fourth-quarter sales of Generics were

258 million, down 1.0% reflecting lower sales in Brazil. In 2015, sales of Generics increased 7.6% to 1,917 million.

Fourth-quarter sales of Oncology were 381 million, down 7.9% impacted by lower sales of Eloxatin in the U.S. In 2015, sales of Oncology were 1,504 million, down 1.9%.

Sales of Jevtana increased 8.1% to 84 million in the fourth quarter led by the U.S. (up 19.2% to 35 million) and Japan where the product was launched in September 2014. In 2015, sales of Jevtana were up 9.5% to 321 million.

Sales of Thymoglobulin were up 12.3% to 69 million and 6.0% to 256 million in the fourth quarter and 2015, respectively.

Fourth-quarter sales of Eloxatin were down 24.3% (to 58 million) reflecting lower sales

in the U.S. which were partially offset by the continued good performance in China. Over the same period, sales of Taxotere decreased 33.8% (to 49 million), reflecting generic

competition especially in Japan. In 2015, sales of Eloxatin and Taxotere were down 0.5% ( 227 million) and down 22.2% ( 222

million), respectively. A generic of Eloxatin was recently introduced in Canada.

Mozobil grew 12.9% (to 38 million) and 16.2% (to 143 million) in the fourth quarter and in 2015, respectively.

Established Rx Products

Fourth-quarter sales of Established Rx Products were 2,699 million, down 10.4%. Excluding AuviQ /Allerject , sales of Established Rx Products were down 6.5%.

Sales of Plavix decreased 14.2% to 455 million in the fourth quarter reflecting generic

competition in Japan beginning in June 2015 (sales in Japan were down 36.5% to 144 million), which was partially offset by continued strong performance in China (up 17.0% to 174 million). In 2015, Plavix decreased 4.1% to 1,929 million with sales in Japan of 695 million (down 12.5%) and China of 660 million (up 13.1%).

Sales of Lovenox were 419 million in the

fourth quarter, down 3.4% impacted by generic competition in the U.S. In Emerging Markets and in Western Europe, sales of Lovenox were up 2.0% (to 151 million) and stable (at 227 million), respectively. Sanofi is aware of competitors